Plain-English translation of NCT05913388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining a new medication called with (a standard immunotherapy drug) can help more patients with advanced melanoma or head and neck squamous cell carcinoma than alone. Half of the participants will receive plus , and half will receive a placebo (a pill that looks identical but has no medicine) plus . Neither you nor the research team will know which group you're in, which helps ensure fair results.
Immunotherapy drugs like help some patients with these cancers, but they don't work for everyone. Researchers believe that adding , a medication that works through a different mechanism in the immune system, might help more patients respond to treatment and live longer.
You likely qualify if…
You likely don't qualify if…
You will take either or a placebo by mouth twice daily, along with standard infusions. You'll have regular clinic visits for blood tests, scans to measure your tumors, and checkups to monitor how you're responding and any side effects. The study will continue until your cancer progresses, you experience unacceptable side effects, or the research team determines the treatment isn't working for you.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Providence Health & Services
Collaborators
Providence Cancer Center, Providence Cancer Center, Earle A. Chiles Research Institute
Enrollment target
~92 participants
Started
February 2024
Primary completion
February 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chris Fountain, RN, ONC
Providence Health & Services
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.